Form 4: 10x Genomics CEO Serge Saxonov Executes Stock Sale

CEO Serge Saxonov sold 5,000 shares of 10x Genomics Class A Common Stock via a pre-arranged Rule 10b5-1 trading plan.

Summary

• Serge Saxonov, CEO of 10x Genomics, sold 5,000 shares of Class A Common Stock on April 14, 2026.
• The shares were sold at a weighted average price of $24.5568 per share, with individual trade prices ranging from $24.49 to $24.70.
• The transaction was conducted under a Rule 10b5-1 trading plan adopted on November 29, 2025.
• Following the sale, the CEO maintains direct ownership of 1,167,273 shares, in addition to indirect holdings through various family trusts.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was pre-planned and represents a minor portion of the CEO's total equity position.

Positives

• The sale was executed under a pre-established Rule 10b5-1 plan, which is a standard mechanism for executives to sell stock without triggering insider trading concerns.

Negatives

• The transaction represents a reduction in the CEO's direct equity stake in the company.

Risks

• Continued insider selling can sometimes be perceived negatively by the market, though this specific sale was pre-planned.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing, as it is a standard disclosure of insider transaction activity.

Industry Context

StockSavvy.ai notes that routine insider selling under 10b5-1 plans is common practice for executives in the biotechnology sector and generally does not signal a change in company fundamentals or strategic direction.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate executives to manage personal liquidity while maintaining compliance with SEC regulations.
• The volume of shares sold (5,000) is relatively small compared to the CEO's total holdings, which is consistent with typical executive diversification strategies.

Related Party Transactions

• The CEO maintains indirect beneficial ownership through the Andromeda Trust, Y/S Descendants' Trust, and Y/S Pot Trust.

Stakeholder Impact

• Minimal impact expected on shareholders as the sale was executed via a pre-arranged plan.

Next Steps

• Continued monitoring of future Form 4 filings for further insider activity.

Key Dates

Keywords

10x Genomics, TXG, Insider Trading, Form 4, Serge Saxonov, Biotechnology, Equity Sale